Article(id=1329835571784036856, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835512791150603, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.11.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1655049600000, receivedDateStr=2022-06-13, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987107462, onlineDateStr=2026-11-18, pubDate=1699545600000, pubDateStr=2023-11-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987107462, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987107462, creator=13701087609, updateTime=1794987107462, updator=13701087609, issue=Issue{id=1329835512791150603, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='11', pageStart='1133', pageEnd='1242', issueExtLink='null', onlineDate='null', pubDate='1699545600000', pubDateStr='2023-11-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794987093398, creator='13701087609', updateTime=1794988063154, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329839580662051474, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835512791150603, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329839580662051475, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835512791150603, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1226, endPage=1231, ext={EN=ArticleExt(id=1329835571993752058, articleId=1329835571784036856, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in the B cell lymphoma-2 inhibitors, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

B cell lymphoma (Bcl)-2 gene is mainly expressed in the outer mitochondrial membrane. It is the major regulator in the apoptotic signaling pathway, and its aberrant expression is closely related to tumor development. Bcl-2 protein, encoded by Bcl-2 gene, regulates apoptosis through protein-protein interactions and has become an important target for the treatment of chronic lymphocytic leukemia (CLL). Most of the Bcl-2 inhibitors are small molecule compounds. Fragment-based drug design approaches that mimic the BH3 structural domain of the Bcl-2 protein have driven the development of Bcl-2 inhibitors. The currently marketed Bcl-2-targeted inhibitor drug venetoclax can effectively treat CLL and small lymphocytic leukemia, and shows better clinical efficacy in B-lymphocyte malignancies, and other Bcl-2 inhibitor drugs that have entered clinical studies also show better development prospects. This article reviewed the mechanism of Bcl-2, and summarized the research progress of Bcl-2 inhibitors in recent years, to provide insights for the further development of Bcl-2 inhibitors.

, authors=Ruling ZHENG, Jianzhong SHENTU*, authorsList=Ruling ZHENG, Jianzhong SHENTU, authorCompany=null, correspAuthors=Jianzhong SHENTU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329835572237021691, articleId=1329835571784036856, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=B淋巴细胞瘤-2抑制剂的研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

B淋巴细胞瘤(B cell lymphoma,Bcl)-2基因主要表达于线粒体外膜,是凋亡信号转导通路中的主要调节因子,其异常表达与肿瘤的发生、发展密切相关。Bcl-2蛋白由Bcl-2基因编码而来,通过蛋白间相互作用调控细胞凋亡,已成为治疗慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)的重要靶点。Bcl-2抑制剂大部分为小分子化合物,基于片段的药物设计方法模拟Bcl-2蛋白的BH3结构域,推动Bcl-2抑制剂的研发。目前已上市的Bcl-2靶向抑制剂维奈克拉(venetoclax)能够有效治疗CLL和小淋巴细胞性白血病,对B淋巴细胞恶性肿瘤表现出较好的临床疗效,其他已进入临床研究的Bcl-2抑制剂也显示出较好的开发前景。现对Bcl-2的作用机制作简要综述,并总结近年Bcl-2抑制剂的研究进展,为其进一步研发提供启示。

, authors=郑如玲, 申屠建中*, authorsList=郑如玲, 申屠建中, authorCompany=null, correspAuthors=申屠建中, authorNote=

郑如玲,硕士研究生,研究方向:临床药理学。

, correspAuthorsNote=
申屠建中,主任药师,研究方向:临床药理学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=lZML5Whljamzg2dhJgMJsA==, magXml=iHNXLUwSBOU07UbaGHgDUA==, pdfUrl=null, pdf=oIGjPgC3yJXD7AwOMupRug==, pdfFileSize=1578136, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=YeA2qyKktz1+U0P/XCWkYg==, mapNumber=null, fund=null)}, authors=[Author(id=1329835572505457152, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835572568371714, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572505457152, language=EN, stringName=Ruling ZHENG, firstName=Ruling, middleName=null, lastName=ZHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835572631286275, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572505457152, language=CN, stringName=郑如玲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=广州医科大学附属第五医院前沿医学研究中心,广州 510700, bio={"content":"

郑如玲,硕士研究生,研究方向:临床药理学。

"}, bioImg=null, bioContent=

郑如玲,硕士研究生,研究方向:临床药理学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835572429959676, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, xref=null, ext=[AuthorCompanyExt(id=1329835572438348285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China), AuthorCompanyExt(id=1329835572446736894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广州医科大学附属第五医院前沿医学研究中心,广州 510700)])]), Author(id=1329835572694200837, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835572773892615, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572694200837, language=EN, stringName=Jianzhong SHENTU, firstName=Jianzhong, middleName=null, lastName=SHENTU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835572845195784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572694200837, language=CN, stringName=申屠建中, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=广州医科大学附属第五医院前沿医学研究中心,广州 510700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835572429959676, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, xref=null, ext=[AuthorCompanyExt(id=1329835572438348285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China), AuthorCompanyExt(id=1329835572446736894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广州医科大学附属第五医院前沿医学研究中心,广州 510700)])])], keywords=[Keyword(id=1329835572958441993, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=EN, orderNo=1, keyword=B cell lymphoma-2), Keyword(id=1329835573021356554, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=EN, orderNo=2, keyword=inhibitor), Keyword(id=1329835573080076811, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=EN, orderNo=3, keyword=apoptosis), Keyword(id=1329835573168157196, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=EN, orderNo=4, keyword=venetoclax), Keyword(id=1329835573218488845, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=CN, orderNo=1, keyword=B淋巴细胞瘤-2基因), Keyword(id=1329835574833295887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=CN, orderNo=2, keyword=抑制剂), Keyword(id=1329835574900404752, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=CN, orderNo=3, keyword=细胞凋亡), Keyword(id=1329835574963319313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, language=CN, orderNo=4, keyword=维奈克拉)], refs=[Reference(id=1329835575059788306, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation[J]. Science, 1984, 226(4678): 1097-1099., articleTitle=null, refAbstract=null), Reference(id=1329835575135285779, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival[J]. Science, 1998, 281(5381): 1322-1326., articleTitle=null, refAbstract=null), Reference(id=1329835575290475028, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch[J]. Nat Rev Cancer, 2002, 2(9): 647-656., articleTitle=null, refAbstract=null), Reference(id=1329835575365972501, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Uren RT, Iyer S, Kluck RM. Pore formation by dimeric BAK and BAX: an unusual pore?[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1726): 20160218., articleTitle=null, refAbstract=null), Reference(id=1329835575445664278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=García-Aranda M, Pérez-Ruiz E, Redondo M. Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy[J]. Int J Mol Sci, 2018, 19(12): 3950., articleTitle=null, refAbstract=null), Reference(id=1329835575537938967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-XL-Bak peptide complex: recognition between regulators of apoptosis[J]. Science, 1997, 275(5302): 983-986., articleTitle=null, refAbstract=null), Reference(id=1329835575609242136, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Kvansakul M, Hinds MG. The Bcl-2 family: structures, interactions and targets for drug discovery[J]. Apoptosis, 2015, 20(2): 136-150., articleTitle=null, refAbstract=null), Reference(id=1329835575684739609, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Thompson CB, Vander Heiden MG. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?[J]. Nat Cell Biol, 1999, 1(8): e209-e216., articleTitle=null, refAbstract=null), Reference(id=1329835575751848474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Dias N, Stein CA. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides[J]. Eur J Pharm Biopharm, 2002, 54(3): 263-269., articleTitle=null, refAbstract=null), Reference(id=1329835575831540251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group[J]. J Clin Oncol, 2006, 24(29): 4738-4745., articleTitle=null, refAbstract=null), Reference(id=1329835575923814940, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=O'brien S, Moore JO, Rai KR, et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase Ⅲ trial of fludarabine plus cyclophosphamide with or without oblimersen[J]. J Clin Oncol, 2009, 27(31): 5208-5212., articleTitle=null, refAbstract=null), Reference(id=1329835576011895325, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Kumthekar P, Ko CH, Paunesku T, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma[J]. Sci Transl Med, 2021, 13(584): eabb3945., articleTitle=null, refAbstract=null), Reference(id=1329835576066421278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Kirsch P, Hartman AM, Hirsch AKH, et al. Concepts and core principles of fragment-based drug design[J]. Molecules (Basel, Switzerland), 2019, 24(23): 4309., articleTitle=null, refAbstract=null), Reference(id=1329835576125141535, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu Y, Mondello P, Erazo T, et al. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to Bcl-2 inhibitor-induced cell death[J]. Proc Natl Acad Sci U S A, 2018, 115(47): 12034-12039., articleTitle=null, refAbstract=null), Reference(id=1329835576192250400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Roberts AW, Davids MS, Pagel JM, et al. Targeting Bcl-2 with venetoclax in relapsed chronic Lymphocytic leukemia[J]. N Engl J Med, 2016, 374(4): 311-322., articleTitle=null, refAbstract=null), Reference(id=1329835576305496609, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment[J]. Am J Hematol, 2019, 94(11): 1266-1287., articleTitle=null, refAbstract=null), Reference(id=1329835576376799778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase Ⅱ pivotal trial[J]. J Clin Oncol, 2018, 36(19): 1973-1980., articleTitle=null, refAbstract=null), Reference(id=1329835576460685859, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Dinardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1): 7-17., articleTitle=null, refAbstract=null), Reference(id=1329835576523600420, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective Bcl-2 inhibitor, achieves antitumor activity while sparing platelets[J]. Nat Med, 2013, 19(2): 202-208., articleTitle=null, refAbstract=null), Reference(id=1329835576607486501, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies[J]. Clin Pharmacol Ther, 2017, 101(1): 89-98., articleTitle=null, refAbstract=null), Reference(id=1329835576699761190, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Vogler M, Dinsdale D, Dyer MJS, et al. ABT-199 selectively inhibits Bcl-2 but not Bcl-2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets[J]. Br J Haematol, 2013, 163(1): 139-142., articleTitle=null, refAbstract=null), Reference(id=1329835576758481447, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2016, 17(6): 768-778., articleTitle=null, refAbstract=null), Reference(id=1329835576825590312, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia[J]. N Engl J Med, 2018, 378(12): 1107-1120., articleTitle=null, refAbstract=null), Reference(id=1329835576875921961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Juárez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential[J]. Drugs Context, 2019, 8: 1-13., articleTitle=null, refAbstract=null), Reference(id=1329835576938836522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Salem AH, Agarwal SK, Dunbar M, et al. Effect of low-and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class Bcl-2 inhibitor[J]. J Clin Pharmacol, 2016, 56(11): 1355-1361., articleTitle=null, refAbstract=null), Reference(id=1329835577014333995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Salem AH, Tao Z, Bueno OF, et al. Expanding the repertoire for “Large Small Molecules”: prodrug ABBV-167 efficiently converts to venetoclax with reduced food effect in healthy volunteers[J]. Mol Cancer Ther, 2021, 20(6): 999-1008., articleTitle=null, refAbstract=null), Reference(id=1329835577089831468, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Blombery P, Anderson MA, Gong J, et al. Acquisition of the recurrent Gly101Val mutation in Bcl-2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia[J]. Cancer Discov, 2019, 9(3): 342-353., articleTitle=null, refAbstract=null), Reference(id=1329835577148551725, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Pan Z, Scheerens H, Li S, et al. Discovery of selective irreversible inhibitors for bruton's tyrosine kinase[J]. ChemMedChem, 2007, 2(1): 58-61., articleTitle=null, refAbstract=null), Reference(id=1329835577211466286, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Deng J, Isik E, Fernandes SM, et al. Bruton's tyrosine kinase inhibition increases Bcl-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia[J]. Leukemia, 2017, 31(10): 2075-2084., articleTitle=null, refAbstract=null), Reference(id=1329835577274380847, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Lin VS, Lew TE, Handunnetti SM, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax[J]. Blood, 2020, 135(25): 2266-2270., articleTitle=null, refAbstract=null), Reference(id=1329835577404404272, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours[J]. Nature, 2005, 435(7042): 677-681., articleTitle=null, refAbstract=null), Reference(id=1329835577488290353, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Hajduk PJ, Gerfin T, Boehlen J, et al. High-throughput nuclear magnetic resonance-based screening[J]. J Med Chem, 1999, 42(13): 2315-2317., articleTitle=null, refAbstract=null), Reference(id=1329835577551204915, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/BAX switch[J]. Cancer Cell, 2005, 8(1): 5-6., articleTitle=null, refAbstract=null), Reference(id=1329835577622508084, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Hauck P, Chao BH, Litz J, et al. Alterations in the Noxa/MCL-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737[J]. Mol Cancer Ther, 2009, 8(4): 883-892., articleTitle=null, refAbstract=null), Reference(id=1329835579224732213, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor[J]. Cancer Res, 2008, 68(9): 3421-3428., articleTitle=null, refAbstract=null), Reference(id=1329835579325395510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to Bcl-2 inhibition: results of a phase Ⅰ study of navitoclax in patients with relapsed or refractory disease[J]. J Clin Oncol, 2012, 30(5): 488-496., articleTitle=null, refAbstract=null), Reference(id=1329835579413475895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival[J]. Cell Death Differ, 2007, 14(5): 943-951., articleTitle=null, refAbstract=null), Reference(id=1329835579501556280, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang G, Nikolovska-Coleska Z, Yang C, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins[J]. J Med Chem, 2006, 49(21): 6139-6142., articleTitle=null, refAbstract=null), Reference(id=1329835579585442361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Loberg RD, Mcgregor N, Ying C, et al. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration[J]. Neoplasia, 2007, 9(12): 1030-1037., articleTitle=null, refAbstract=null), Reference(id=1329835579652551226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Yi H, Qiu MZ, Yuan L, et al. Bcl-2/Bcl-XL inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma[J]. Cancer Med, 2020, 9(12): 4197-4206., articleTitle=null, refAbstract=null), Reference(id=1329835579736437307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Luo Q, Pan W, Zhou S, et al. A novel Bcl-2 Inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-p53 inhibitor in diffuse large B-Cell lymphoma[J]. Oncol Res, 2020, 28(4): 331-344., articleTitle=null, refAbstract=null), Reference(id=1329835579811934780, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Casara P, Davidson J, Claperon A, et al. S55746 is a novel orally active Bcl-2 selective and potent inhibitor that impairs hematological tumor growth[J]. Oncotarget, 2018, 9(28): 20075-20088., articleTitle=null, refAbstract=null), Reference(id=1329835579879043645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Ferenczy GG, Keserű GM. Enthalpic efficiency of ligand binding[J]. J Chem Inf Model, 2010, 50(9): 1536-1541., articleTitle=null, refAbstract=null), Reference(id=1329835579988095550, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Hu N, Guo Y, Xue H, et al. Abstract 3077: preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models[J]. Cancer Res, 2020, 80(16 Supplement): 3077., articleTitle=null, refAbstract=null), Reference(id=1329835580051010111, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Patterson CM, Balachander SB, Grant I, et al. Design and optimisation of dendrimer-conjugated Bcl-2/XL inhibitor, AZD0466, with improved therapeutic index for cancer therapy[J]. Commun Biol, 2021, 1(4): 112., articleTitle=null, refAbstract=null), Reference(id=1329835580113924672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Balachander SB, Tabatabai A, Wen S, et al. AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-XL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models[J]. Cancer Res, 2020, 80(16 Supplement): 56., articleTitle=null, refAbstract=null), Reference(id=1329835580185227841, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=D'aguanno S, Del BD. Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer[J]. Cells, 2020, 9(5): 1287., articleTitle=null, refAbstract=null), Reference(id=1329835580277502530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Berger S, Procko E, Margineantu D, et al. Computationally designed high specificity inhibitors delineate the roles of Bcl-2 family proteins in cancer[J]. Elife, 2016, e20352(5): 1-31., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329835572429959676, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, xref=null, ext=[AuthorCompanyExt(id=1329835572438348285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China), AuthorCompanyExt(id=1329835572446736894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广州医科大学附属第五医院前沿医学研究中心,广州 510700)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.11.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.11.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.11.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.11.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1699545600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
B淋巴细胞瘤-2抑制剂的研究进展
郑如玲 , 申屠建中 *
世界临床药物 | 综述评论 2023,44(11): 1226-1231
收起
收藏切换
世界临床药物 |综述评论 2023 , 44 (11) : 1226 -1231
B淋巴细胞瘤-2抑制剂的研究进展
全屏
[Author(id=1329835572505457152, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835572568371714, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572505457152, language=EN, stringName=Ruling ZHENG, firstName=Ruling, middleName=null, lastName=ZHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835572631286275, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572505457152, language=CN, stringName=郑如玲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=广州医科大学附属第五医院前沿医学研究中心,广州 510700, bio={"content":"

郑如玲,硕士研究生,研究方向:临床药理学。

"}, bioImg=null, bioContent=

郑如玲,硕士研究生,研究方向:临床药理学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835572429959676, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, xref=null, ext=[AuthorCompanyExt(id=1329835572438348285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China), AuthorCompanyExt(id=1329835572446736894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广州医科大学附属第五医院前沿医学研究中心,广州 510700)])]), Author(id=1329835572694200837, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835572773892615, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572694200837, language=EN, stringName=Jianzhong SHENTU, firstName=Jianzhong, middleName=null, lastName=SHENTU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835572845195784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, authorId=1329835572694200837, language=CN, stringName=申屠建中, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=广州医科大学附属第五医院前沿医学研究中心,广州 510700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835572429959676, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, xref=null, ext=[AuthorCompanyExt(id=1329835572438348285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China), AuthorCompanyExt(id=1329835572446736894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835571784036856, companyId=1329835572429959676, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广州医科大学附属第五医院前沿医学研究中心,广州 510700)])])]
郑如玲, 申屠建中*
作者信息
  • 广州医科大学附属第五医院前沿医学研究中心,广州 510700
通讯作者:
申屠建中,主任药师,研究方向:临床药理学。
作者简介:

郑如玲,硕士研究生,研究方向:临床药理学。

Advances in the B cell lymphoma-2 inhibitors
Ruling ZHENG, Jianzhong SHENTU*
Affiliations
  • Innovation Centre for Advanced Interdisciplinary Medicine, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, Guangdong Province, China
出版时间: 2023-11-10 doi: 10.13683/j.wph.2023.11.017
文章导航
收藏切换

B淋巴细胞瘤(B cell lymphoma,Bcl)-2基因主要表达于线粒体外膜,是凋亡信号转导通路中的主要调节因子,其异常表达与肿瘤的发生、发展密切相关。Bcl-2蛋白由Bcl-2基因编码而来,通过蛋白间相互作用调控细胞凋亡,已成为治疗慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)的重要靶点。Bcl-2抑制剂大部分为小分子化合物,基于片段的药物设计方法模拟Bcl-2蛋白的BH3结构域,推动Bcl-2抑制剂的研发。目前已上市的Bcl-2靶向抑制剂维奈克拉(venetoclax)能够有效治疗CLL和小淋巴细胞性白血病,对B淋巴细胞恶性肿瘤表现出较好的临床疗效,其他已进入临床研究的Bcl-2抑制剂也显示出较好的开发前景。现对Bcl-2的作用机制作简要综述,并总结近年Bcl-2抑制剂的研究进展,为其进一步研发提供启示。

B淋巴细胞瘤-2基因  /  抑制剂  /  细胞凋亡  /  维奈克拉

B cell lymphoma (Bcl)-2 gene is mainly expressed in the outer mitochondrial membrane. It is the major regulator in the apoptotic signaling pathway, and its aberrant expression is closely related to tumor development. Bcl-2 protein, encoded by Bcl-2 gene, regulates apoptosis through protein-protein interactions and has become an important target for the treatment of chronic lymphocytic leukemia (CLL). Most of the Bcl-2 inhibitors are small molecule compounds. Fragment-based drug design approaches that mimic the BH3 structural domain of the Bcl-2 protein have driven the development of Bcl-2 inhibitors. The currently marketed Bcl-2-targeted inhibitor drug venetoclax can effectively treat CLL and small lymphocytic leukemia, and shows better clinical efficacy in B-lymphocyte malignancies, and other Bcl-2 inhibitor drugs that have entered clinical studies also show better development prospects. This article reviewed the mechanism of Bcl-2, and summarized the research progress of Bcl-2 inhibitors in recent years, to provide insights for the further development of Bcl-2 inhibitors.

B cell lymphoma-2  /  inhibitor  /  apoptosis  /  venetoclax
郑如玲, 申屠建中. B淋巴细胞瘤-2抑制剂的研究进展. 世界临床药物, 2023 , 44 (11) : 1226 -1231 . DOI: 10.13683/j.wph.2023.11.017
Ruling ZHENG, Jianzhong SHENTU. Advances in the B cell lymphoma-2 inhibitors[J]. World Clinical Drug, 2023 , 44 (11) : 1226 -1231 . DOI: 10.13683/j.wph.2023.11.017

参考文献 引证文献
排序方式:
[1]
Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation[J]. Science, 1984, 226(4678): 1097-1099.
[2]
Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival[J]. Science, 1998, 281(5381): 1322-1326.
[3]
Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch[J]. Nat Rev Cancer, 2002, 2(9): 647-656.
[4]
Uren RT, Iyer S, Kluck RM. Pore formation by dimeric BAK and BAX: an unusual pore?[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1726): 20160218.
[5]
García-Aranda M, Pérez-Ruiz E, Redondo M. Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy[J]. Int J Mol Sci, 2018, 19(12): 3950.
[6]
Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-XL-Bak peptide complex: recognition between regulators of apoptosis[J]. Science, 1997, 275(5302): 983-986.
[7]
Kvansakul M, Hinds MG. The Bcl-2 family: structures, interactions and targets for drug discovery[J]. Apoptosis, 2015, 20(2): 136-150.
[8]
Thompson CB, Vander Heiden MG. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?[J]. Nat Cell Biol, 1999, 1(8): e209-e216.
[9]
Dias N, Stein CA. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides[J]. Eur J Pharm Biopharm, 2002, 54(3): 263-269.
[10]
Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group[J]. J Clin Oncol, 2006, 24(29): 4738-4745.
[11]
O'brien S, Moore JO, Rai KR, et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase Ⅲ trial of fludarabine plus cyclophosphamide with or without oblimersen[J]. J Clin Oncol, 2009, 27(31): 5208-5212.
[12]
Kumthekar P, Ko CH, Paunesku T, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma[J]. Sci Transl Med, 2021, 13(584): eabb3945.
[13]
Kirsch P, Hartman AM, Hirsch AKH, et al. Concepts and core principles of fragment-based drug design[J]. Molecules (Basel, Switzerland), 2019, 24(23): 4309.
[14]
Liu Y, Mondello P, Erazo T, et al. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to Bcl-2 inhibitor-induced cell death[J]. Proc Natl Acad Sci U S A, 2018, 115(47): 12034-12039.
[15]
Roberts AW, Davids MS, Pagel JM, et al. Targeting Bcl-2 with venetoclax in relapsed chronic Lymphocytic leukemia[J]. N Engl J Med, 2016, 374(4): 311-322.
[16]
Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment[J]. Am J Hematol, 2019, 94(11): 1266-1287.
[17]
Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase Ⅱ pivotal trial[J]. J Clin Oncol, 2018, 36(19): 1973-1980.
[18]
Dinardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1): 7-17.
[19]
Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective Bcl-2 inhibitor, achieves antitumor activity while sparing platelets[J]. Nat Med, 2013, 19(2): 202-208.
[20]
Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies[J]. Clin Pharmacol Ther, 2017, 101(1): 89-98.
[21]
Vogler M, Dinsdale D, Dyer MJS, et al. ABT-199 selectively inhibits Bcl-2 but not Bcl-2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets[J]. Br J Haematol, 2013, 163(1): 139-142.
[22]
Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2016, 17(6): 768-778.
[23]
Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia[J]. N Engl J Med, 2018, 378(12): 1107-1120.
[24]
Juárez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential[J]. Drugs Context, 2019, 8: 1-13.
[25]
Salem AH, Agarwal SK, Dunbar M, et al. Effect of low-and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class Bcl-2 inhibitor[J]. J Clin Pharmacol, 2016, 56(11): 1355-1361.
[26]
Salem AH, Tao Z, Bueno OF, et al. Expanding the repertoire for “Large Small Molecules”: prodrug ABBV-167 efficiently converts to venetoclax with reduced food effect in healthy volunteers[J]. Mol Cancer Ther, 2021, 20(6): 999-1008.
[27]
Blombery P, Anderson MA, Gong J, et al. Acquisition of the recurrent Gly101Val mutation in Bcl-2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia[J]. Cancer Discov, 2019, 9(3): 342-353.
[28]
Pan Z, Scheerens H, Li S, et al. Discovery of selective irreversible inhibitors for bruton's tyrosine kinase[J]. ChemMedChem, 2007, 2(1): 58-61.
[29]
Deng J, Isik E, Fernandes SM, et al. Bruton's tyrosine kinase inhibition increases Bcl-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia[J]. Leukemia, 2017, 31(10): 2075-2084.
[30]
Lin VS, Lew TE, Handunnetti SM, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax[J]. Blood, 2020, 135(25): 2266-2270.
[31]
Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours[J]. Nature, 2005, 435(7042): 677-681.
[32]
Hajduk PJ, Gerfin T, Boehlen J, et al. High-throughput nuclear magnetic resonance-based screening[J]. J Med Chem, 1999, 42(13): 2315-2317.
[33]
Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/BAX switch[J]. Cancer Cell, 2005, 8(1): 5-6.
[34]
Hauck P, Chao BH, Litz J, et al. Alterations in the Noxa/MCL-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737[J]. Mol Cancer Ther, 2009, 8(4): 883-892.
[35]
Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor[J]. Cancer Res, 2008, 68(9): 3421-3428.
[36]
Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to Bcl-2 inhibition: results of a phase Ⅰ study of navitoclax in patients with relapsed or refractory disease[J]. J Clin Oncol, 2012, 30(5): 488-496.
[37]
Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival[J]. Cell Death Differ, 2007, 14(5): 943-951.
[38]
Wang G, Nikolovska-Coleska Z, Yang C, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins[J]. J Med Chem, 2006, 49(21): 6139-6142.
[39]
Loberg RD, Mcgregor N, Ying C, et al. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration[J]. Neoplasia, 2007, 9(12): 1030-1037.
[40]
Yi H, Qiu MZ, Yuan L, et al. Bcl-2/Bcl-XL inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma[J]. Cancer Med, 2020, 9(12): 4197-4206.
[41]
Luo Q, Pan W, Zhou S, et al. A novel Bcl-2 Inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-p53 inhibitor in diffuse large B-Cell lymphoma[J]. Oncol Res, 2020, 28(4): 331-344.
[42]
Casara P, Davidson J, Claperon A, et al. S55746 is a novel orally active Bcl-2 selective and potent inhibitor that impairs hematological tumor growth[J]. Oncotarget, 2018, 9(28): 20075-20088.
[43]
Ferenczy GG, Keserű GM. Enthalpic efficiency of ligand binding[J]. J Chem Inf Model, 2010, 50(9): 1536-1541.
[44]
Hu N, Guo Y, Xue H, et al. Abstract 3077: preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models[J]. Cancer Res, 2020, 80(16 Supplement): 3077.
[45]
Patterson CM, Balachander SB, Grant I, et al. Design and optimisation of dendrimer-conjugated Bcl-2/XL inhibitor, AZD0466, with improved therapeutic index for cancer therapy[J]. Commun Biol, 2021, 1(4): 112.
[46]
Balachander SB, Tabatabai A, Wen S, et al. AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-XL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models[J]. Cancer Res, 2020, 80(16 Supplement): 56.
[47]
D'aguanno S, Del BD. Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer[J]. Cells, 2020, 9(5): 1287.
[48]
Berger S, Procko E, Margineantu D, et al. Computationally designed high specificity inhibitors delineate the roles of Bcl-2 family proteins in cancer[J]. Elife, 2016, e20352(5): 1-31.
2023年第44卷第11期
13
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.11.017
  • 接收时间:2022-06-13
  • 首发时间:2026-11-18
  • 出版时间:2023-11-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-06-13
基金
作者信息
    广州医科大学附属第五医院前沿医学研究中心,广州 510700

通讯作者:

申屠建中,主任药师,研究方向:临床药理学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.11.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏